NCT02923531: A trial that was reported late by X4 Pharmaceuticals
This trial has reported, although it was 380 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02923531 |
|---|---|
| Title | A Phase 1B/2A Trial Adding X4P-001 in Patients Receiving Nivolumab for Treatment of Advanced Clear Cell Renal Cell Carcinoma |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Dec. 7, 2016 |
| Completion date | Aug. 8, 2018 |
| Required reporting date | Aug. 8, 2021, midnight |
| Actual reporting date | Aug. 23, 2022 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 380 |